Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC